Cohen Amends MANGOCEUTICALS Stake Filing

TL;DR

Cohen updated his 13D filing for MANGOCEUTICALS, INC. on Aug 27.

AI Summary

Jacob D. Cohen filed an amendment (No. 3) to Schedule 13D on August 27, 2024, regarding his holdings in MANGOCEUTICALS, INC. The filing indicates a change in the date of the event requiring this statement to August 26, 2024. Cohen's address is listed as 15110 N. Dallas Parkway, Suite 600, Dallas, Texas.

Why It Matters

This amendment signals a potential shift in significant beneficial ownership for MANGOCEUTICALS, INC., which could impact the stock's trading dynamics.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant changes in ownership, which can lead to increased volatility and uncertainty for the stock.

Key Players & Entities

• Jacob D. Cohen (person) — Filing person and beneficial owner
• MANGOCEUTICALS, INC. (company) — Subject company
• August 27, 2024 (date) — Filing date of amendment
• August 26, 2024 (date) — Date of event requiring filing

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
• $0.32 — of common stock at an exercise price of $0.32 per share and an expiration date of Dec
• $1.10 — of common stock at an exercise price of $1.10 per share and an expiration date of Aug

Filing Documents

• formsc13da.htm (SC 13D/A) — 65KB
• 0001493152-24-034062.txt ( ) — 66KB

From the Filing

SC 13D/A 1 formsc13da.htm UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* MANGOCEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 56270V106 (CUSIP Number) Jacob D. Cohen 15110 N. Dallas Parkway, Suite 600 Dallas, Texas 75248 (214) 242-9619 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 26, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “ filed ” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 56270V106 Schedule 13D/A Amendment No. 3 Page 2 of 5 1. Name of Reporting Person Jacob D. Cohen 2. Check the Appropriate Box if a Member of a Group. (a) (b) 3. SEC Use Only 4. Source of Funds OO 5. Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) 6. Citizenship or Place of Organization United Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 1,750,000 shares* (1) 8. Shared Voting Power 9,075,000 shares* 9. Sole Dispositive Power 1,750,000 shares* (1) 10. Shared Dispositive Power 9,075,000 shares* 11. Aggregate Amount Beneficially Owned by Each Reporting Person 10,825,000 shares* 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares. 13. Percent of Class Represented by Amount in Row (11) 34.2%* 14. Type of Reporting Person IN * All percentages are based on 29,905,803 shares of Common Stock outstanding as of August 27, 2024, as confirmed by the Issuer’s transfer agent on such date. (1) Includes 1,250,000 shares of common stock issuable upon exercise of options to purchase shares of common stock at an exercise price of $0.32 per share and an expiration date of December 28, 2028, and 500,000 shares of common stock issuable upon exercise of options to purchase shares of common stock at an exercise price of $1.10 per share and an expiration date of August 31, 2027, which have vested, or which vest, within 60 days of August 27, 2024. CUSIP No. 56270V106 Schedule 13D/A Amendment No. 3 Page 3 of 5 1. Name of Reporting Person The Tiger Cub Trust 2. Check the Appropriate Box if a Member of a Group. (a) (b) 3. SEC Use Only 4. Source of Funds OO 5. Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e). 6. Citizenship or Place of Organization Texas Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power -0- shares 8. Shared Voting Power 9,075,000 shares 9. Sole Dispositive Power -0- shares 10. Shared Dispositive Power 9,075,000 shares 11. Aggregate Amount Beneficially Owned by Each Reporting Person 9,075,000 shares 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares. 13. Percent of Class Represented by Amount in Row (11) 30.3%* 14. Type of Reporting Person OO * All percentages are based on 29,905,803 shares of Common Stock outstanding as of August 27, 2024, as confirmed by the Issuer’s transfer agent on such date. CUSIP No. 56270V106 Schedule 13D/A Amendment No. 3 Page 4 of 5 This Amendment No. 3 (the “ Amendment ”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “ Commission ”) on May 3, 2023, as amended by Amendment No.1 thereto filed with the Commission on January 2, 2024 and Amendment No. 2 thereto filed with the Commission on June 5, 2024, by Jacob D. Cohen and The Tiger Cub Trust (the Schedule 13D as amended and modified to date, the “ Schedule 13D ”). Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Schedule 13D. Except as expressly amended and supplemented

View Full Filing

View this SC 13D/A filing on SEC EDGAR